...Philippines, Vietnam, Laos, Cambodia, Thailand, Malaysia, Singapore, Brunei, Myanmar, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Palau...

...the deal was the second largest venture round raised by a Spanish biotech, behind only Palau Pharma S.A....

...Actavis acquired worldwide rights to Palau's antifungal agent albaconazole, which is in development to treat vulvo-vaginal...
...broad spectrum oral antifungal has completed a Phase II trial to treat distal subungual onychomycosis. Palau...
...Sage Group advised Palau. Actavis declined to disclose details, and Palau could not be reached. Palau Pharma S.A....

...atopic dermatitis, which is expected to start in 4Q13, will include specific monitoring for agranulocytosis. Palau Pharma S.A....
...allergic asthma and rhinitis. Yeadon said he did not know how ZPL-3893787 might differ from Palau's...
...Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Palau Pharma S.A....

...to treat allergic rhinitis induced by nasal allergen challenge in 24 otherwise healthy allergic patients. Palau Pharma S.A....

...volunteers, single-ascending doses of oral UR-63325 were well tolerated with no specific adverse events identified. Palau...
...Data were presented at the European Academy of Allergy and Clinical Immunology meeting in London. Palau Pharma S.A....

...German Phase II trial in 134 patients. The company licensed the compound from Grupo Uriach's Palau...

...by academics and internal preclinical research to support its hypotheses. Last week, the company in-licensed Palau...
...good, the company plans to start a Phase IIa trial in 2008. Under the deal, Palau...

...Grupo Uriach's Palau Pharma subsidiary granted Affectis an exclusive worldwide license to cimicoxib to treat all...
...and schizophrenia and expects to start a Phase IIa trial to treat depression this year. Palau...
...undisclosed upfront fee and is eligible for milestones and royalties. Further terms were not disclosed. Palau...